Eradication of small intestinal bacterial overgrowth and oro-cecal transit in diabetics

Hepato-Gastroenterology

Volumn 49, Issue 48, 2002, Pages 1582-1586

  Cuoco, Lucio ^a   Montalto, Massimo ^a   Jorizzo, Regina Anna ^a   Santarelli, Luca ^a   Arancio, Fabiola ^a   Cammarota, Giovanni ^a   Gasbarrini, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Bacterial overgrowth; Diabetic patients; Eradication; Oro cecal transit time; Small intestine

Indexed keywords

LACTULOSE; RIFAXIMIN;

ADULT; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; BACTERIAL INFECTION; BACTERIAL OVERGROWTH; CARDIOVASCULAR SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; ERADICATION THERAPY; FEMALE; GASTROINTESTINAL MOTILITY; HUMAN; HYDROGEN BREATH TEST; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE TRANSIT TIME; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SMALL INTESTINE; STATISTICAL ANALYSIS;

ADULT; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; BREATH TESTS; CASE-CONTROL STUDIES; DIABETES MELLITUS; FEMALE; GASTROINTESTINAL TRANSIT; HUMANS; INTESTINE, SMALL; LACTULOSE; MALE; MIDDLE AGED; RIFAMYCINS; TREATMENT OUTCOME;

EID: 0036839945     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Abrahamsson H: Gastrointestinal motility disorders in patients with diabetes mellitus. J Intern Med 1995; 237(4):403-409.
2. Folwaczny C, Riepl R, Tschop M, Landgraf R: Gastrointestinal involvement in patients with diabetes mellitus: Part I (first of two parts). Epidemiology, pathophysiology, clinical findings. Z Gastroenterol 1999; 37(9):803-815.
3. Minocha A, Katragadda R, Rahal PS, Ries A: Erythromycin shortens orocaecal transit time in diabetic male subjects: a double-blind placebo-controlled study. Aliment Pharmacol Ther 1995; 9(5):529-533.
4. Virally-Monod M, Tielmans D, Kevorkian JP, Bouhnik Y, Flourie B, Porokhov B, et al: Chronic diarrhoea and diabetes mellitus: prevalence of small intestinal bacterial overgrowth. Diabetes Metab 1998; 24(6):530-536.
5. Ewing DJ, Clarke BF: Diagnosis and management of diabetic autonomic neuropathy. BMJ 1982; 285:916-918.
6. Norby Rasmessen S, Haagen Nielsen O, Justesen T, Jacobsen IE, Lave J, Magrid E: Comparison of an open and a closed tube system for collection of jejunal juice. Scand J Gastroenterol 1983; 18:353-357.
7. Riordan SM, McIver CJ, Wakefield D, Bolin TD, Duncombe VM, Thomas MC: Small intestinal bacterial overgrowth in the symptomatic elderly. Am J Gastroenterol 1997; 92(1):47-51.
8. Kong MF, Horowitz M, Jones KL, Wishart JM, Harding PE: Natural history of diabetic gastroparesis. Diabetes Care 1999; 22(3):503-507.
9. Miller MA, Parkman HP, Urbain JLC, Brown KL, Donahue DJ, Knight LC, et al: Comparison of scintigraphic and lactulose breath hydrogen test for assessment of orocecal transit time. Lactulose accelerates small bowel transit. Dig Dis Sci 1997; 42(1):10-18.
10. Horowitz M, Wishart JM, Jones KL, Hebbard GS: Gastric emptying in diabetes: an overview. Diabet Med 1996; 13:S16-22.
11. Stone BG, Gavaler JS, Belle SH, Shreiner DP, Peleman RR, Sarva RP, et al: Impairmentof gallbladder emptying in diabetes mellitus. Gastroenterology 1988; 85:170-176.
12. Russo A, Frasser R, Horowitz M: The effect of acute hyperglicaemia on small intestinal motility in normal subjects. Diabetologia 1996; 39(8):984-989.
13. Lozovsky D, Saller CF, Kopin IJ: Dopamine receptor binding is increased in diabetic rats. Science 1981; 214:1031-1032.
14. Mansi C, Savarino V, Vigneri S, Sciaba L, Perilli D, Mele MR, et al: Effect of D2-dopamine receptor antagonist levosulpiride on diabetic cholecystoparesis: a souble-blind crossover study. Aliment Pharmacol Ther 1995; 9:185-189.
15. Talley NG: Review article: 5-hydroxytryptamine agonist and antagonist in the modulation and gastrointestinal motility and sensation: clinical implications. Aliment pharmacol Ther 1992; 6:273-289.
16. Jebbink RJ, Samson M, Bruijs PP, Braveboer B, Akkermans LM, Vanberge-Henegouwen GP, et al: Hyperglycemia induces abnormalities of gastric myoelectrical activity in patients with type I diabetes mellitus. Gastroenterology 1994; 107:1390-1397.
17. Veglio MP, Carpano Maglioli P, Tonda L: Autonomic neuropathy in non-insulin dependent diabetes mellitus: correlation with age, sex, duration and metabolic control of diabetes mellitus. Diab Metab 1990; 16:200-206.
18. Horowitz M, Edelbroek M, Fraser R, Maddox A, Washart J: Disordered gastric motor function in diabetes mellitus. Recent insights into prevalence, pathophysiology, clinical relevance and treatment. Scand J Gastroenterol 1191; 26:673-684.
19. Husebye E, Hellstrom PM, Midtveit T: Intestinal microflora stimulates myoelectrical activity of rat small intestine by promoting cyclic initiation and aboral propagation of migrating myoelectric complex. Dig Dis Sci 1994; 39:946-956.
20. Caenepeel P, Janssens J, Vantrappen G, Eyssen H, Coremans G: Interdigestive myoelectric complex in germfree rats. Dig Dis Sci 1989; 34:1180-1184.
21. Stotzer PO, Bjornsson ES, Abrahamsson H: Interdigestive and postprandial motility in small intestinal bacterial overgrowth. Scand J Gastroenterol 1996; 31:875-880.
22. Stacher G: Motility disorders of the stomach and duodenum. In: Kumar D. Wingate D (Eds.). An illustrated guide to gastrointestinal motility. 2nd Edition. Edinburgh, London, Madrid, Melbourne, New York, Tokyo: Churchill Livingstone, 1993; pp. 522-537.
23. Van Assche G, Barbara G, Deng Y, Lovato P, Gauldie J, Collins SM: Neurotrasmitters modulate cytokine-stimulated interleukin 6 secretion in rat intestinal smooth muscle cells. Gastroenterology 1999; 116:346-353.
24. Spengler U, Stellaard F, Ruckdeschel G, Scheurlen C, Kruis W: Small intestinal transit, bacterial growth, and bowel habits in diabetes mellitus. Pancreas 1989; 4(1):65-70.
25. Lin HC, Zhao XT, Wang L: Intestinal transit is more potently inhibited by fat in the distal (ileal brake) than in the proximal (jejunal brake) gut. Dig Dis Sci 1997; 42(1):19-25.
26. Evans AJ, Krentz AJ: Should cisapride be avoided in patients with diabetic gastroparesis? J Diabetes Complications 1999; 13(5-6):314-315.
27. Gillis JC, Brogden RN: Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995; 49:467-484.